EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series

Li Zhao, Vinit Singh, Anthony Ricca, Patrick Lee

Journal of Medical Cases · 2022-05 · 13 (5) · 240-243

DOI: 10.14740/jmc3918 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Medical Cases, 2022-05. Verfasst von Li Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA. Die Arbeit wurde bisher 23-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Anti-programmed death-1 inhibitorPancreatic ductal adenocarcinomaPembrolizumabSurvival

Autor:innen und Institutionen

  • Department of Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA.

Zitieren

APA

Zhao, L., Singh, V., Ricca, A., & Lee, P. (2022). Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series. Journal of Medical Cases, 13(5), 240-243. https://doi.org/10.14740/jmc3918

Vancouver

Zhao L, Singh V, Ricca A, Lee P. Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series. Journal of Medical Cases. 2022;13(5):240-243. doi:10.14740/jmc3918

BibTeX
@article{Zhao2022,
  author = {Zhao, Li and Singh, Vinit and Ricca, Anthony and Lee, Patrick},
  title = {Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series},
  journal = {Journal of Medical Cases},
  year = {2022},
  volume = {13},
  number = {5},
  pages = {240--243},
  doi = {10.14740/jmc3918}
}
Kostenlos starten →